ACTRN12606000424505已完成1 期
A Phase 1 Single-Center, Randomized, Placebo-Controlled, Double-Blind Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Candidate Topical Antimicrobial (NEO101) in the Reduction of Propionibacterium acnes among Healthy Young Adult Men
eosil, Inc.0 个研究点目标入组 30 人开始时间: 2006年10月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 45 Years（—）
- 性别
- Male
入选标准
- •Sign an informed consent;- are in general good health;-do not have active acne lesions on the forehead;- are colonized with P. acnes, as demonstrated by a screening culture with a P. acnes count of >10,000/cm2 on facial skin (forehead);- have not used any form of topical or systemic antibiotics within 28 days prior to enrollment;- compliant with adequate birth control (defined).
排除标准
- •Have concomitant dermatologic or medical condition(s) which may interfere wtih the investigator's ability to evaluate the subject's response to the study drug;- have atopic dermatitis, active allergic rhinitis, or nasal polyps, seborrheic dermatitis or psoriasis, or any facial piercing;- have a history of hypersensitivity or allergic to parabens, sodium sulfite or any other ingredient in the vehicle formulation.
研究者
相似试验
已完成
1 期
A Phase 1, Single-Center, Randomized, Placebo-Controlled, Ascending Single-Dose Study of the Pharmacokinetics, Safety, and Tolerability of Oral XG005 in Healthy VolunteersChronic PainACTRN12617001330336Xgene Pharmaceutical Inc.50
已完成
1 期
A phase 1, randomized, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic profiles of OLX10010 in healthy subjects compared to placeboISRCTN64317949OliX Pharmaceuticals, Inc.48
已完成
不适用
A Phase 1, Single-Center, Single-Blind, Placebo and Propofol Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous (IV) Infusion Doses of ABP-700anesthesiaNL-OMON41980Annovation Biopharma, Inc. (a wholly owned subsidiary of The Medicines Company, Inc.)72
已完成
不适用
A Phase 1, Single-Center, Double-Blind, Placebo Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ABP-700 after a Single Ascending Bolus DoseanesthesiaNL-OMON40883Annovation Biopharma, Inc.60
进行中（未招募）
1 期
A Study of LY3844583 in Healthy Participants and Participants With Atopic DermatitisJPRN-jRCT2031220745Wakayama Naohiko86